Tetrahydroisoquinolines and Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 81-96

  Ledoux, Mark S ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847132106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-19     Document Type: Chapter

References (88)

1. Langston, J. W. et al., 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219, 979, 1983.
2. Ballard, P. A., Tetrud, J. W., and Langston, J. W., Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases, Neurology, 35, 949, 1985.
3. Yoshida, M. et al., Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues, Adv. Neurol., 60, 207, 1993.
4. Kajita, M. et al., Endogenous synthesis of N-methylnorsalsolinol in rat brain during in vivo microdialysis with epinine, J. Chromatogr., B654, 263, 1993.
5. Nagatsu, T., Isoquinoline neurotoxins in the brain and Parkinson’s disease, Neurosci. Res., 29, 99, 1997.
6. McNaught, K. S. et al., Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Biochem. Pharmacol., 50, 1903, 1995.
7. Makino, Y. et al., 1988. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: Compounds related to Parkinson’s disease, Life Sci., 43, 373, 1988.
8. Makino, Y. et al., Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization, Biomed. Environ. Mass Spectrom., 19, 415, 1990.
9. Niwa, T. et al., Presence of tetrahydroisoquinoline, a parkinsonism related compound, in foods, J. Chromatogr., 493, 345, 1989.
10. Deng, Y. et al., Assay for the (R)and (S)-enantiomers of salsolinols in biological samples and foods with ionpair high-performance liquid chromatography using beta-cyclodextrin as a chiral mobile phase additive, J. Chromatogr. B. Biomed. Sci. Appl., 689, 313, 1997.
11. Niwa, T. et al., Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroisoquinoline in parkinsonian and normal human brains, Biochem. Biophys. Res. Comm., 144, 1084, 1987.
12. Nagatsu, T. and Yoshida, M., An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterine in the nigrostriatal regions, Neurosci. Lett., 87, 178, 1988.
13. Ogawa, M. et al., The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: immunohistochemical studiestyrosine hydroxylase, Biogenic Amines, 6, 436, 1989.
14. Kawai, H. et al., Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: Uptake by dopamine transporter and activity to induce parkinsonism, J. Neurochem., 70, 745, 1998.
15. Maruyama, W. et al., Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, Adv. Neurol., 60, 207, 1993.
16. Maruyama, W. et al., A neurotoxin N-methyl(R)salsolinol induces apoptotic cell death in differentiated human dopaminergic neuroblastoma SH-SY5Y cells, Neurosci. Lett., 232, 147, 1997.
17. Naoi, M et al., Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: Biochemical, pathological, and behavioral studies, Brain Res., 709, 285, 1996.
18. Naoi, M. et al., Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons, Toxicology 153, 123, 2000.
19. Kotake, Y. et al., 1-benzyl 1-2-3-4 tetrahydroisoquinoline as a parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF, J. Neurochem. 65, 2633, 1995.
20. Kotake, Y. et al., Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate, Neurosci. Lett., 217, 69, 1996.
21. Kotake, Y. et al., Neurotoxicity of an endogenous brain amine, 1-benzyl-1,2,3,4-tetrahydroisoquinoline, in organotypic slice co-culture of mesencephalon and striatum, Neuroscience, 117, 63, 2003.
22. Nijima, K. et al., N-methylisoquinolinium ion (NMIQ+) destroys cultured mesencephalic dopamine neurons, Biogenic Amines, 8, 61, 1991.
23. Nishi, K. et al., Neurotoxic effects of 1-methyl-4-phenylpyridinium (MPP+) and tetrahydroisoquinoline derivatives on dopaminergic neurons in ventral mesencephalic-striatal co-culture, Neurodegeneration, 3, 33, 1994.
24. Tanner, C.M. et al., Parkinson disease in twins: An etiologic study, JAMA, 281, 341, 1999.
25. Rommelspacher, H. and Susilo, R., Tetrahydroisoquinolines and beta-carbolines: Putative natural substances in plants and mammals, Prog. Drug Res., 29, 415, 1985.
26. Siddhuraju, P., Becker, K., and Makkar, H. P., Studies on the nutritional composition and antinutritional factors of three different germplasm seed materials of an underutilized tropical legume, Mucuna pruriens var. Utilis, J. Agric. Food Chem., 48, 6048, 2000.
27. Collins, M. A. et al., Brain and plasma tetrahydroisoquinolines in rats: Effects of chronic ethanol intake and diet, J. Neurochem., 55, 1507, 1990.
28. Ohta, S. et al., Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ) a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer, Life Sci., 46, 599, 1990.
29. Bon, M. A. et al., Neurogenetic correlates of Parkinson’s disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism, Neurosci. Lett., 266, 149, 1999.
30. Kikuchi, K. et al., Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline, Drug Metab. Dispos., 19, 257, 1991.
31. Thümen, A. et al., N-Methyl-norsalsolinol, a putative dopaminergic neurotoxin, passes through the bloodbrain barrier in vivo, Neuroreport, 13, 25, 2002.
32. Origitano, T., Hannigan, J., and Collins, M. A., Rat brain salsolinol and blood-brain barrier. Brain Res., 224, 446, 1981
33. Musshoff, F. et al., Determination of dopamine and dopamine-derived (R)-/(S)-salsolinol and norsalsolinol in various human brain areas using solid-phase extraction and gas chromatography/mass spectrometry, Forensic Sci. Int., 113, 359, 2000.
34. Abe, K. et al., Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4,-tetrahydroisoquinolineinduced parkinsonism in the mouse, Brain Res., 907, 134, 2001.
35. Jellinger, K.A., Post mortem studies in Parkinson’s disease—is it possible to detect brain areas for specific symptoms?, J. Neural. Transm. Suppl., 56, 1, 1999.
36. Gesi, M. et al., The role of the locus coeruleus in the development of Parkinson’s disease, Neurosci. Biobehav. Rev., 24, 655, 2000.
37. Del Tredici, K. et al., Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol., 61, 413, 2002.
38. Den Hartog Jager, W. A. and Bethlem, J., The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans, J. Neurol. Neurosurg. Psychiatry, 23, 283, 1960.
39. Rajput, A. H. and Rozdilsky, B., Dysautonomia in Parkinsonism: A clinicopathological study, J. Neurol. Neursurg. Psychiatry, 39, 1092, 1976.
40. Gainetdinov, R. R. et al., Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter, J. Neurochem., 69, 1322, 1997.
41. Moron, J.A. et al., Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines, J. Neurosci., 22, 389, 2002.
42. Storch, A. et al., Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson’s disease: Tudies using heterologous expression systems of the dopamine transporter, Biochem. Pharmacol., 63, 909, 2002.
43. Cohen, G., Mytilineou, C., and Barrett, R. E., 6,7-dihydroxytetrahydroisoquinoline: Uptake and storage by peripheral sympathetic nerve of the rat, Science, 175, 1269, 1972.
44. Tennyson, V. M. et al., 6,7-dihydroxytetrahdroisoquinoline: Electron microscopic evidence for uptake into the amine-binding vesicles in sympathetic nerves of rat iris and pineal gland, Brain Res., 51, 161, 1973.
45. Konradi, C. et al., Variations of monoamines and their metabolites in the human brain putamen, Brain Res., 579, 285, 1992.
46. Yamakawa, T. et al., Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain, Neurosci. Lett., 276, 68, 1999.
47. Naoi, M. et al., A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl-(R)salsolinol, Neurosci. Lett., 212, 183, 1996.
48. Naoi, M. et al., (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes, Ann. Neurol., 43, 212, 1998.
49. Parsons, R. B. et al., High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson’s disease, Neurosci. Lett., 342, 13, 2003.
50. Aoyama, K. et al., Nicotinamide-N-methyl-transferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson’s disease, Neurosci. Lett., 298, 78, 2001.
51. Booth, R. G., Castagnoli, N., Jr., and Rollema, H., Intracerebral microdialysis neurotoxicity studies of quinoline and isoquinoline derivatives related to MPTP/MPP+, Neurosci. Lett., 100, 306, 1989.
52. Suzuki, K. et al., Selective inhibition of complex I by N-methylisoquinolinium ion and N-methyl-1,2,3,4-tetrahydroisoquinoline in isolated mitochondria prepared from mouse brain, J. Neurol. Sci., 109, 219, 1992.
53. Hirata, Y. and Nagatsu, T., Inhibition of tyrosine hydroxylation in tissue slices of the rat striatum by 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine, Brain Res., 337, 193, 1985.
54. Scholz, J., Bamberg, H., and Moser, A., N-methyl-norsalsolinol, an endogenous neurotoxin, inhibits tyrosine hydroxylase activity in the rat brain nucleus accumbens in vitro, Neurochem. Int., 31, 845, 1997.
55. Maruyama, W. et al., An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY-SY5Y cells, J. Neurochem., 69, 322, 1997.
56. Akao, Y. et al., Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3, Neurosci. Lett., 267, 153, 1999
57. Maruyama, W. et al., Transfection-enforced Bcl-2 overexpression and an antiparkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, J. Neurochem., 78, 727, 2001.
58. Perry, T. L., Jones, K., and Hansen, S., Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice, Neurosci. Lett., 85, 101, 1988.
59. Perry, T. L. et al., 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets, Neurosci. Lett., 75, 65, 1987.
60. Fukuda, T., 2-methyl-1,2,3,4-tetrahydroisoquinoline does dependently reduce the number of tyrosine hydroxylase-immunoreactive cells in the substantia nigra and the locus ceruleus of C57BL/6J mice, Brain Res., 639, 325, 1994.
61. Moser, A. et al., Rotational behaviour and neurochemical changes in unilateral N-methyl-norsalsolinol and 6-hydroxydopamine lesioned rats, Exp. Brain Res., 112, 89, 1996.
62. Antkiewicz-Michaluk, L. et al., Different action on dopamine catabolic pathways of two endogenous1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties, J. Neurochem., 78, 100, 2001.
63. Niwa, T. et al., Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonism and normal human brains, Biochem. Biophys. Res. Comm., 177, 603, 1991.
64. Müller, T. et al., No increase of synthesis of (R) salsolinol in Parkinson’s disease, Mov. Disord., 14, 514, 1999.
65. Maruyama, W. et al., An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson’s disease, Neurosci. Lett., 262, 13, 1999.
66. Moser, A. et al., Presence of N-methyl-norsalsolinol in the CSF: Correlations with dopamine metabolites of patients with Parkinson’s disease, J. Neurol. Sci., 131, 183, 1995.
67. Grandinetti, A. et al., Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease, Am. J. Epidemiol., 139, 1129, 1994.
68. Paganini-Hill, A. et al., Risk factors for Parkinson’s disease: The leisure world cohort study, Neuroepidemiology, 20, 118, 2001.
69. Soto-Otero, R. et al., Interaction of 1,2,3,4-tetrahydroisoquinoline with some components of cigarette smoke: Potential implications for Parkinson’s disease. Biochem. Biophys. Res Comm., 222, 607, 1996.
70. Soto-Otero, R. et al., Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-beta-carboline by cigarette smoke, Neurosci. Lett., 298, 187, 2001.
71. Parrado, J. et al., The endogenous amine 1-methyl-1,2,3,4-tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP+, J. Neurochem., 75, 65, 2000.
72. Tasaki, Y., et al., 1-methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydroisoquinoline-treated mouse, prevents parkinsonismlike behavior abnormalities, J. Neurochem., 57, 1940, 1991.
73. Yamakawa, T. and Ohta, S., Isolation of 1-methyl-1,2,3,4-tetrahydroisoquinoline-synthesizing enzyme from rat brain: A possible Parkinson’s disease-preventing enzyme, Biochem. Biophys. Res. Commun., 236, 676, 1997.
74. Absi, E. et al., Decrease of 1-methyl-1,2,3,4-tetrahydroisoquinoline synthesizing enzyme activity in the brain areas of aged rat, Brain Res., 955, 161, 2002.
75. Caparros-Lefebvre, D., Elbaz, A., and the Caribbean Parkinsonian Study Group, Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: A case-control study, Lancet, 354, 281, 1999.
76. Caparros-Lefebvre, D. et al., Guadeloupean parkinsonism: A cluster of progressive supranuclear palsy-like tauopathy, Brain, 125, 801, 2002.
77. de Silva, R. et al., The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson’s disease, Neurosci. Lett., 330, 201, 2002.
78. Farrer, M. et al., The tau H1 haplotype is associated with Parkinson’s disease in the Norwegian population, Neurosci. Lett., 322, 83, 2002.
79. Lannuzel A, et al., Toxicity of Annonaceae for dopaminergic neurons: Potential role in atypical Parkinsonism in Guadeloupe, Mov. Disord., 17, 84, 2002.
80. Lannuzel, A. et al., Role of the mitochondrial complex I inhibitor annonacin in Parkinsonism, Neurology, 60(Suppl. 1), A331, 2003.
81. Yuan, S.-S. F. et al., Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase andcauses cytotoxicity in a Baxand caspase-3-related pathway, Life Sci., 72, 2853, 2003.
82. Maruyama, W. et al., A dopaminergic neurotoxin, 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl(R)salsolinol, and its oxidation product, 1,2(N)-dimethyl-6,7-dihydroxyisoquinolinium ion, accumulate in the nigro-striatal system of the human brain, Neurosci. Lett., 223, 61, 1997.
83. Storch, A. et al., 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism, Brain Res., 855, 67, 2000.
84. Naoi, M. et al., Dopamine-derived endogenous Nmethyl-(R)-salsolinol. Its role in Parkinson’s disease, Neurotoxicol. Teratol., 24, 579, 2002.
85. Chun, H. S. et al., Dopaminergic cell death induced by MPP(+), oxidant an specific neurotoxicants shares the common molecular mechanism, J. Neurochem., 76, 1010, 2001.
86. Yoshida, M., Niwa, T., and Nagatsu, T., Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes, Neurosci. Lett., 119, 109, 1990.
87. Sandler, M. et al., Tetrahydroisoquinoline alkaloids: In vivo metabolite of L-dopa in man, Nature, 241, 439, 1973.
88. Antkiewicz-Michaluk, L. et al., Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: Advantage of a new high-performance liquid chromatography methodology, Biol. Psychiatry, 42, 514, 1997.